• ÖZ

This study was conducted to investigate the efficacy of pre-phase therapy in preventing tumor lysis syndrome (TLS) in cases with high tumor burden. This study involved 42 lymphoma patients with moderate to high risk of developing TLS. All of the cases underwent a prephase treatment which consisted of 1 mg of vincristine first day and 100 mg/day of prednisolone for seven days. Afterwards, planned conventional chemotherapy regimens were given. The development of laboratory TLS was evaluated by the end of the conventional cytotoxic treatment. Among the patients, 85.6% had B cell neoplasia and 14,4% had T cell lymphoblastic lymphoma (TCLL). The risk of TLS was high in 57.2% of the cases and intermediate in 42.8%. A total of 42.8% cases developed laboratory TLS after conventional treatment following prephase therapy. On the other hand, there were 7.1% patients who exceeded the normal laboratory value limits. In addition, 2.3% of the cases had only clinical findings of TLS. Treatment response was complete in 57.1% and partial in 40.5% with respect to the findings of PET-CT. Prephase therapy may decrease the severity of TLS in cases with a high tumor burden. Prephase therapy may be used in the initial phase in cases at moderate-to-high risk for TLS

• ÖZ

RAS and BRAF mutation and primary tumour sideness are prognostic and predictive factors in metastatic colorectal cancer (mCRC). We aimed to investigate RAS-BRAF mutation rates and responses to biologic agents the effects of tumour sideness on survival. This was a retrospective study conducted at three Turkish institutes. 303 patients with mCRC who were examined for tumour RAS and 172 examined for tumour BRAF mutations between 2006-2018. A total of 303 (M/F= 186/117) patients were included to study. Median age was 63 (range: 23-86) years. Median follow-up was 22.8 (range: 19.1-26.4) months. In the RAS wild type population; ad-dition to anti-EGFR agents to standard chemotherapy (CT) had better outcomes than Bevacizumab+CT. Median PFS was improved with anti-EGFR agents (Respectively PFS; 14.5 months, 8.7 months) (log rank p= 0.007 HR= 0.59). Median OS was similar between CT+anti-EGFR and CT+Bevacizumab arms (Respectively OS; 29.3 months, 21.7 months) (log rank p= 0.418; HR= 0.75). RAS muta-tion rates were similar between right colon cancer (RCC) and left colon cancer (LCC), BRAF mutation rates were significantly increased in RCC (22.2 vs 2.7%, p< 0.0001). RCC (24.1%) had worse prognosis than LCC (75.9%). However, this difference was not significant (PFS: 10.4 vs 10.0 months (log rank p= 0.136) , OS: 21.5 vs 23.1 months (log rank p= 0.436). We concluded that in the patients with RAS wild type tumours, CT and anti-EGFR combination was reasonable approach for first line treatment. BRAF mutation, irrespective of CT regimen, was associated with poor survival and more common in RCC patients.

• ÖZ

The promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) fusion gene is present in 98% of the patients with acute promyelocytic leukemia (APL), the M3 subtype of acute myeloid leukemia (AML). All-trans retinoic acid (ATRA) is widely used to treat patients with APL. Nucleolar Protein 7 (NOL7) is a tumor suppressor gene regulated by retinoid X receptor (RXR). The 6p23 chromosomal region, where NOL7 is located, is associated with many cancers, including AML. Here, we aimed to investigate the effect of NOL7 in two AML cell lines (the PML-RARA-positive NB4 cell line and the PML-RARA-negative HL60 cell line) and in the resistance to ATRA. For this purpose, we knocked down NOL7 expression by using short interfering RNA (siRNA) and stimulated the cells with ATRA. Apoptosis, cell viability, proliferation, and granulocytic differentiation analyses were performed. Our findings show that granulocytic differentiation was blocked in ATRA-treated NB4 cells 24 hours after NOL7 siRNA transfection when the expression of NOL7 had been reduced by 81%. Downregulation of NOL7 had no apparent effect on the cellular proliferation and apoptosis. Our study suggests that ATRA-induced granulocytic differentiation is inhibited in NOL7-downregulated NB4 cells. These results suggest that NOL7 expression contributes to ATRA-induced granulocytic differentiation and loss of NOL7 might be involved in the development of ATRA resistance

• ÖZ

The prognosis of melanoma is extremely poor. There are no biomarker that indicate the prognosis. The indirect markers of the antitumoral response such as the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), derived NLR (dNLR), absolute neutrophil count (ANC), absolute lymphocyte count (ALC) etc. have recently begun to be emphasized. Increased NLR, PLR and dNLR as a consequence of chronic inflammation have been found to be associated with poor prognosis in many cancers. The aim of this study is explore the role of this parameters in patients with early-stage melanoma. We retrospectively evaluated 120 patients admitted to our clinic with stage I-III melanoma with ANC, ALC, absolute platelet count(APC), as well as NLR, dNLR, and PLR values at the time of diagnosis, relaps and metastasis and evaluate their impact on prognosis. Patients with active infection, receiving steroids, with a chronic inflammatory disease that may alter the hematological parameters, and those with another malignancy other than melanoma were excluded. The median follow-up was 52 months. OS and DFS were significantly worse in patients with an NLR above 2.84. Also, in patients with a dNLR value above 1.96 (p= 0.007). The were no relationship between PLR value, OS and DFS, and between gender and OS. OS was significantly lower in patients over 65 years of age (p< 0.001). These results suggested that haematological parameters can be used to estimate the prognosis of melanoma. These results suggested that haematological parameters can be used to estimate the prognosis of melanoma

• ÖZ

Background: Bibliometric and Altmetric analyses highlight key publications. The role of social media platforms in the promotion, dissemination and display of medical literature has improved greatly over the last few years. The hypothesis is that highly cited cancer articles would correlate positively with Altmetric attention scores (AAS). ‘Cancer’ as a search term was entered into Thomson Reuter’s Web of Science database to identify all articles in the last decade. The 50 most cited articles were analysed by topic, journal, author, year, and AAS. By bibliometric criteria, eligible articles numbered 1,465,400 and the median (range) citation number was 3601.5 (2556-23725). The most cited article in the top 50 list was “Global cancer statistics’’ published by Jemal A. et al. in 2011, while the highest AAS was published by Siegel RL.et.al., ‘’Cancer Statistics’’, in 2017. New England Journal of Medicine published most articles (n= 14). Positive correlation was between average citations per year and AAS (r= 0.491 p< 0.01) but no correlation was found between citation number and AAS (r= 0.184 p= 0.2). Bibliometric and Altmetric analysis provide important but different perspectives regarding article impact. Our findings provide useful information on the dissemination of cancer research among the general public.